Reslizumab
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials - The Lancet Respiratory Medicine
Dosing and Administration
NICE changes mind and backs new drug for severe asthma | Nursing Times
Reslizumab | New Drug Approvals
Llega reslizumab, terapia adicional reduce exacerbaciones asma grave
Teva-Handok wins approval for anti-asthma injection < Pharma < Article - KBR
Medication Detail
Israeli Pharma gets FDA Approval for Asthma Antibody
Cinqair (reslizumab) Injection for treatment of Severe Asthma and an Eosinophilic Phenotype - Clinical Trials Arena
CINQAIR® (reslizumab) Injection – About Asthma Control
Cinqair Reslizumab Injection
Australian Public Assessment Report Reslizumab
A program supporting CINQAIR® (reslizumab) Injection patients
Cinqair (reslizumab) Injection for treatment of Severe Asthma and an Eosinophilic Phenotype - Clinical Trials Arena
TA479 Review decision paper
FDA approves Teva's Cinqair (reslizumab) Injection
Chest Medicine Made Easy-Dr Deepu: FDA approves Injectable drug for uncontrolled Asthma
Older Patients with Asthma Do Well with Reslizumab | RT
Reslizumab - Anwendung, Wirkung, Nebenwirkungen | Gelbe Liste
Cinqair (Reslizumab) 100mg/10mL Injection – Apothera
Brand name: Auvi-Q
Rx Item-Cinqair (Reslizumab) 10Mg/Ml Inj Sinle Use Vial 10Ml By Teva Respiratory
761033Orig1s000
